GSK And Valeant Partner On Epilepsy Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.
You may also be interested in...
Five Positive Opinions From EU's CHMP Brightens Up The New Year
New molecular entities from Valeant/GSK, Eisai, Sanofi and Novartis make the grade for the EU's scientific panel at its January meeting.
Five Positive Opinions From EU's CHMP Brightens Up The New Year
New molecular entities from Valeant/GSK, Eisai, Sanofi and Novartis make the grade for the EU's scientific panel at its January meeting.
Valeant/GSK's Anti-Epileptic Potiga Faces Advisory Committee In Mid-August
High rate of adverse event-related dropouts in clinical trials could be a key focus of panel's discussion of ezogabine, also known as retigabine.